Paperonium

Stomach cancer · Clin Cancer Res · 2025

11 of 16 patients responded, but the paper’s range of likely rates is calculated for 13.

The paper: 11 of 16 respondedRange for 13 of 16 responderssame as the paper’sCorrect range for 11 of 16just above 40%Trial’s plan: under 40% =not working54.3 to 95.9%41.3 to 89.0%0%20%40%60%80%100%no one responded
The paper:11 of 16 respondedRange for 13 of16 responderssame as the paper’sCorrect rangefor 11 of 16just above 40%Trial’s plan:under 40% =not working95.9%54.3%89.0%41.3%0%50%100%no one responded

Percent of patients who responded (dot) and the range of likely rates (bar)

The paper says

A 16-patient stomach-cancer trial’s main result: tumors shrank enough to count as a response in 11 patients (68.8%). With so few patients, the paper adds a range of likely response rates for patients like these, calculated from that count: 54.3% to 95.9%.

Its own data show

That range matches, to the last digit, a standard calculation for 13 of 16. The same calculation for 11 gives 41.3% to 89.0%, and other standard ones start at 46% or lower. Eleven is right: the results table counts 11 responses, 3 steady and 2 growing tumors; only the line beside the range says 13.

With few patients, luck can push a result up or down; the range shows how far. The trial’s plan said a rate under 40% would suggest the treatment isn’t working. The correct range starts at 41.3%, just above that line, not at 54.3%, well clear of it. Allowing for luck, the treatment still beats that line, but only just.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial · Clin Cancer Res (2025) · doi:10.1158/1078-0432.CCR-24-3528